Literature DB >> 16215315

Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.

Serdar Arisan1, Elif Damla Buyuktuncer, Narcin Palavan-Unsal, Turhan Caşkurlu, Omer Onur Cakir, Erbil Ergenekon.   

Abstract

INTRODUCTION: Recent experiments have demonstrated that polycomb group gene enhancer zeste homolog 2 (EZH2) is highly expressed in many cancer types. Therefore, we aim to demonstrate EZH2 gene expression in transitional cell bladder cancer. PATIENTS AND METHODS: The reverse transcriptase-polymerase chain reaction (RT-PCR) was used for detection of EZH2 mRNA levels in healthy and cancerous human bladder specimens. Also, expression of the particular protein was determined by Western blotting and immunohistochemistry to confirm RT-PCR results.
RESULTS: Gradually increased expression of EZH2 was detected by mRNA and protein levels in highly advanced bladder cancer specimens. In contrast, 100% of control subjects were negative for EZH2 expression. The expression of EZH2 was more frequent in G3 (92%) than G1-G2 (62-63%) and more frequent in T1-2 (72-85%) than Ta (56%). Western blot analysis results confirm the RT-PCR results.
CONCLUSIONS: EZH2 overexpression precedes high frequencies of proliferation and the gradual advance of bladder cancer. These observations suggest that deregulated expression of EZH2 is associated with bladder carcinoma. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16215315     DOI: 10.1159/000087804

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  25 in total

Review 1.  The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer.

Authors:  Michael Zeidler; Celina G Kleer
Journal:  J Mol Histol       Date:  2006-07-20       Impact factor: 2.611

Review 2.  Emerging EZH2 Inhibitors and Their Application in Lymphoma.

Authors:  Jennifer K Lue; Jennifer E Amengual
Journal:  Curr Hematol Malig Rep       Date:  2018-10       Impact factor: 3.952

3.  Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression.

Authors:  Sharon Hensley Alford; Katherine Toy; Sofia D Merajver; Celina G Kleer
Journal:  Breast Cancer Res Treat       Date:  2011-05-26       Impact factor: 4.872

4.  Clinicopathological and prognostic significance of EZH2 expression in upper urinary tract carcinoma.

Authors:  Akimasa Hayashi; Teppei Morikawa; Taketo Kawai; Haruki Kume; Shumpei Ishikawa; Yukio Homma; Masashi Fukayama
Journal:  Virchows Arch       Date:  2014-01-21       Impact factor: 4.064

Review 5.  Transcriptional deregulation underlying the pathogenesis of small cell lung cancer.

Authors:  Dong-Wook Kim; Keun-Cheol Kim; Kee-Beom Kim; Colin T Dunn; Kwon-Sik Park
Journal:  Transl Lung Cancer Res       Date:  2018-02

Review 6.  Histone modifications: Targeting head and neck cancer stem cells.

Authors:  John M Le; Cristiane H Squarize; Rogerio M Castilho
Journal:  World J Stem Cells       Date:  2014-11-26       Impact factor: 5.326

Review 7.  Connections between epigenetic gene silencing and human disease.

Authors:  Timothy J Moss; Lori L Wallrath
Journal:  Mutat Res       Date:  2007-01-21       Impact factor: 2.433

8.  Spatiotemporal expression of Ezh2 in the developing mouse cochlear sensory epithelium.

Authors:  Yan Chen; Wenyan Li; Wen Li; Renjie Chai; Huawei Li
Journal:  Front Med       Date:  2016-09-07       Impact factor: 4.592

9.  NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2.

Authors:  G M De Donatis; E Le Pape; A Pierron; Y Cheli; V Hofman; P Hofman; M Allegra; K Zahaf; P Bahadoran; S Rocchi; C Bertolotto; R Ballotti; T Passeron
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

10.  Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder.

Authors:  Stefan Hinz; Carsten Kempkensteffen; Frank Christoph; Michèle Hoffmann; Hans Krause; Mark Schrader; Martin Schostak; Kurt Miller; Steffen Weikert
Journal:  J Cancer Res Clin Oncol       Date:  2007-08-11       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.